Association of Acute and Chronic Hyperglycemia With Acute Ischemic Stroke Outcomes Post‐Thrombolysis: Findings From Get With The Guidelines‐Stroke

Background Hyperglycemia has been associated with adverse outcomes in patients with acute ischemic stroke (AIS) and may influence outcomes after tissue plasminogen activator (tPA). We sought to analyze the association of acute and chronic hyperglycemia on clinical outcomes in tPA‐treated patients. Methods and Results We identified 58 265 AIS patients from 1408 sites who received tPA from 2009 to 2013 in Get With The Guidelines‐Stroke. Acute hyperglycemia at admission was defined as a plasma glucose level >140 mg/dL. Chronic hyperglycemia was defined by plasma glycosylated hemoglobin (HbA1c) >6.5%. Post‐tPA outcomes were analyzed using logistic regression. Blood glucose >140 mg/dL and HbA1c >6.5 were associated with worse clinical outcomes (symptomatic intracranial hemorrhage [sICH], life‐threatening hemorrhage, and in‐hospital mortality and length of stay) in diabetic and nondiabetic patients. Among patients with documented history of diabetes, increasing admission glucose up to 200 mg/dL was associated with increased adjusted odds ratio (aOR) of in‐hospital mortality (aOR, 1.07) and sICH (aOR, 1.05) per 10 mg/dL increase in blood glucose. Increasing HbA1C to 8% was associated with increased odds of in‐hospital mortality (aOR, 1.19) and sICH (aOR, 1.16) per 1% increase in HbA1c. Similar findings were observed in patients without a documented history of diabetes. There was no further increase in poor outcomes above the blood glucose level of 200 mg/dL or HbA1c >8. Conclusion Acute and chronic hyperglycemia are both associated with increased mortality and worse clinical outcomes in AIS patients treated with tPA. Controlled trials are needed to determine whether acute correction of hyperglycemia can improve outcomes after thrombolysis.

[1]  P. Michel,et al.  Intravenous Insulin Treatment in Acute Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2014, International journal of stroke : official journal of the International Stroke Society.

[2]  Askiel Bruno,et al.  The Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Protocol: A Randomized, Blinded, Efficacy Trial of Standard vs. Intensive Hyperglycemia Management in Acute Stroke , 2014, International journal of stroke : official journal of the International Stroke Society.

[3]  M. Brainin,et al.  Diabetes and thrombolysis for acute stroke: a clear benefit for diabetics , 2014, European journal of neurology.

[4]  Brett M. Kissela,et al.  Factors Influencing the Decline in Stroke Mortality: A Statement From the American Heart Association/American Stroke Association , 2014, Stroke.

[5]  M. Wintermark,et al.  Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.

[6]  Eric E. Smith,et al.  Risk Score for Intracranial Hemorrhage in Patients With Acute Ischemic Stroke Treated With Intravenous Tissue-Type Plasminogen Activator , 2012, Stroke.

[7]  Gary A. Ford,et al.  Predicting the Risk of Symptomatic Intracerebral Hemorrhage in Ischemic Stroke Treated With Intravenous Alteplase: Safe Implementation of Treatments in Stroke (SITS) Symptomatic Intracerebral Hemorrhage Risk Score , 2012, Stroke.

[8]  Peter Austin,et al.  The iScore Predicts Effectiveness of Thrombolytic Therapy for Acute Ischemic Stroke , 2012, Stroke.

[9]  P. O S I T I O N S T A T E M E N T.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[10]  V. Basevi.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[11]  Eric E. Smith,et al.  Quality of Care and Outcomes in Patients With Diabetes Hospitalized With Ischemic Stroke: Findings From Get With the Guidelines–Stroke , 2010, Stroke.

[12]  Eric E. Smith,et al.  Age-Related Differences in Characteristics, Performance Measures, Treatment Trends, and Outcomes in Patients With Ischemic Stroke , 2010, Circulation.

[13]  Eric E. Smith,et al.  Characteristics, Performance Measures, and In-Hospital Outcomes of the First One Million Stroke and Transient Ischemic Attack Admissions in Get With The Guidelines-Stroke , 2010, Circulation. Cardiovascular quality and outcomes.

[14]  P. O S I T I O N S T A T E M E N T,et al.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[15]  Joanna Wardlaw,et al.  Stroke treatment with alteplase given 3·0–4·5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial , 2009, The Lancet Neurology.

[16]  N. Sattar,et al.  Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials , 2009, The Lancet.

[17]  J. Serena,et al.  The Prognostic Value of Capillary Glucose Levels in Acute Stroke: The GLycemia in Acute Stroke (GLIAS) Study , 2009, Stroke.

[18]  Li Liang,et al.  Get With the Guidelines–Stroke Is Associated With Sustained Improvement in Care for Patients Hospitalized With Acute Stroke or Transient Ischemic Attack , 2009, Circulation.

[19]  G. Moneta,et al.  Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke , 2009 .

[20]  D. Tanné,et al.  A risk score to predict intracranial hemorrhage after recombinant tissue plasminogen activator for acute ischemic stroke. , 2008, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[21]  G Schlaug,et al.  The HAT Score , 2008, Neurology.

[22]  L. Schwamm,et al.  Hospital treatment of patients with ischemic stroke or transient ischemic attack using the "Get With The Guidelines" program. , 2008, Archives of internal medicine.

[23]  G. Albers,et al.  Symptomatic Intracerebral Hemorrhage following Thrombolytic Therapy for Acute Ischemic Stroke: A Review of the Risk Factors , 2007, Cerebrovascular Diseases.

[24]  J. Arenillas,et al.  Acute Hyperglycemia State Is Associated With Lower tPA-Induced Recanalization Rates in Stroke Patients , 2005, Stroke.

[25]  A. Tuttolomondo,et al.  Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke: data from the European BIOMED Stroke Project. , 2003, Stroke.

[26]  J. Arenillas,et al.  Effects of Admission Hyperglycemia on Stroke Outcome in Reperfused Tissue Plasminogen Activator–Treated Patients , 2003, Stroke.

[27]  J. Broderick,et al.  Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial , 2002, Neurology.

[28]  J. Rotich,et al.  Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke , 2002, Neurology.

[29]  Andrew M. Demchuk,et al.  Markers of Increased Risk of Intracerebral Hemorrhage After Intravenous Recombinant Tissue Plasminogen Activator Therapy for Acute Ischemic Stroke in Clinical Practice: The Multicenter rt-PA Acute Stroke Survey , 2002, Circulation.

[30]  H. Adams,et al.  Acute blood glucose level and outcome from ischemic stroke , 1999, Neurology.

[31]  A. Demchuk,et al.  Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. , 1999, Stroke.

[32]  Joakim Bjorkdahl.  Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long term follow up study: , 1997 .

[33]  T. N. t-P. S. S. Group,et al.  Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. , 1997, Stroke.

[34]  E. Shahar,et al.  Trends in Diabetes Prevalence Among Stroke Patients and the Effect of Diabetes on Stroke Survival: the Minnesota Heart Survey , 1994, Diabetic medicine : a journal of the British Diabetic Association.

[35]  B. Sobel,et al.  Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.